With a beta of 0.44 signaling the company’s resistance to market conditions, Eli Lilly and Company (NYSE:LLY) has a high anticipated 5-year EPS growth of 41.87%, making the stock a strong contender in ...

JPMorgan said Eli Lilly is enrolling about 500,000 new obesity drug patients per month, and maintains more than 60% share in ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

That makes EPS growth an attractive quality for any company. Over the last three years, Eli Lilly has grown EPS by 12% per year. That's a good rate of growth, if it can be sustained.

Eli Lilly and Company (NYSE:LLY) Number of Hedge Fund Holders In Q2 2024: 100. Projected EPS Growth Rate: 50.6%. Eli Lilly and Company (NYSE:LLY) is a mega pharmaceutical company that sells ...

Eli Lilly projects 32% revenue growth for 2025, fueled by incretin expansion and new launches. 1mo. ... Earnings per share for 2025 are projected at $22.50 to $24.00.

Eli Lilly not only beat earnings per share (EPS) expectations with a non-GAAP EPS of $2.58 compared to the analysts' consensus figure of $2.47, but also showcased an impressive revenue increase.

Summary. Eli Lilly's shares reached new all-time highs after the company increased full-year revenue and EPS guidance. The company's growth is currently supply-constrained and the growth of ...

TD Cowen analyst Steve Scala has maintained their bullish stance on LLY stock, giving a Buy rating yesterday. Steve Scala has given his Buy rat ...

We recently compiled a list of the 10 Most Promising Growth Stocks According to Hedge Funds. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against ...

Eli Lilly and Company (NYSE:LLY) last week reported its latest yearly results, which makes it a good time for investors to dive in and see if the business is performing in line with expectations.

Eli Lilly and Company LLY reported second-quarter 2023 adjusted earnings per share of $2.11, which beat the Zacks Consensus Estimate of $1.98.